Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to $13.1 million.

  • Taysha Gene Therapies' Share-based Compensation fell 2.14% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 9.53%. This contributed to the annual value of $13.1 million for FY2024, which is 65.76% up from last year.
  • Per Taysha Gene Therapies' latest filing, its Share-based Compensation stood at $13.1 million for FY2024, which was up 65.76% from $7.9 million recorded in FY2023.
  • Over the past 5 years, Taysha Gene Therapies' Share-based Compensation peaked at $18.2 million during FY2021, and registered a low of $3.4 million during FY2020.
  • Over the past 3 years, Taysha Gene Therapies' median Share-based Compensation value was $13.1 million (recorded in 2024), while the average stood at $13.0 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first spiked by 442.16% in 2021, then plummeted by 56.19% in 2023.
  • Yearly analysis of 5 years shows Taysha Gene Therapies' Share-based Compensation stood at $3.4 million in 2020, then spiked by 442.16% to $18.2 million in 2021, then dropped by 0.78% to $18.0 million in 2022, then slumped by 56.19% to $7.9 million in 2023, then soared by 65.76% to $13.1 million in 2024.